Cyamemazine is a phenothiazine antipsychotic drug primarily prescribed for the treatment of schizophrenia and anxiety associated with psychosis, notable for its distinct anxiolytic properties within the… Read more









Cyamemazine is a phenothiazine antipsychotic drug primarily prescribed for the treatment of schizophrenia and anxiety associated with psychosis, notable for its distinct anxiolytic properties within the first-generation neuroleptic class. This category provides essential reference standards required by pharmaceutical laboratories for rigorous analytical testing, method validation, and quality control of this active ingredient. The collection includes a comprehensive range of synthetic and degradative impurities, such as N-demethylcyamemazine and 2-cyanophenothiazine, which are critical for accurate impurity profiling and routine monitoring. Additionally, the list features specific metabolites like cyamemazine sulfoxide and stable isotope labelled compounds, including deuterated versions of the parent molecule. These high-quality materials support precise quantification and identification during formulation development and stability studies, ensuring compliance with established regulatory standards throughout the pharmaceutical product lifecycle.